Korian gained almost 6% yesterday following a robust pace in the FY16 results, coming in line with the consensus and the group’s guidance (September 2016). Sales were up 15.8% on a reported basis, fuelled by acquisitions completed by Korian with a strong contribution from the German Casa Reha. EBITDA leaped by 23.5% (EBITDA margin at 14.1% vs 13.3% in 2015) boosted by c.€12m of non-recurring income (EBITDA margin at 13.7%, i.e. +40bp excluding this one-off). Sales grew by 3.8% lfl,
20 Mar 2017
Upbeat FY16 results, strong operating support from acquisitions
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Upbeat FY16 results, strong operating support from acquisitions
Clariane SE (CLARI:PAR) | 0 0 1.9% | Mkt Cap: 1,957m
- Published:
20 Mar 2017 -
Author:
Bérénice Lacroix -
Pages:
3
Korian gained almost 6% yesterday following a robust pace in the FY16 results, coming in line with the consensus and the group’s guidance (September 2016). Sales were up 15.8% on a reported basis, fuelled by acquisitions completed by Korian with a strong contribution from the German Casa Reha. EBITDA leaped by 23.5% (EBITDA margin at 14.1% vs 13.3% in 2015) boosted by c.€12m of non-recurring income (EBITDA margin at 13.7%, i.e. +40bp excluding this one-off). Sales grew by 3.8% lfl,